二代测序在新生儿遗传性球形红细胞增多症诊断中的应用分析
该病例系列研究纳入49例经二代测序确诊的遗传性球形红细胞增多症(HS)患儿,分析其临床与遗传学特征。新生儿期起病组贫血更重且诊断困难,二代测序可有效实现早期分子诊断,对不明原因新生儿重度高胆红素血症及溶血性贫血的病因诊断具有重要价值。
要点
- ANK1和SPTB基因是HS患儿主要致病基因,55%为既往未报道的新变异。
- 新生儿期起病HS贫血更重、接受光疗及输血比例更高,临床诊断困难。
- 二代测序可有效实现新生儿HS早期分子诊断,助力病因明确。
核心结论
- ANK1基因和SPTB基因是HS患儿的主要致病基因。
- 新生儿期起病HS贫血程度较重、临床诊断困难,应用二代测序可有效实现早期分子诊断。
- 二代测序对不明原因新生儿重度高胆红素血症及溶血性贫血的病因诊断具有重要价值。
研究设计与样本
- 病例系列研究,纳入2016年6月至2025年6月5个中心经二代测序确诊的49例HS患儿。
- 收集入院年龄、性别、家族史、起病时间、临床症状体征、实验室检查及基因检测结果等临床资料。
- 按起病年龄分组比较临床特征、诊断经过及治疗情况,并按致病基因及变异类型分组探讨基因型-表型关系。
- 组间比较采用Mann-Whitney U检验、Kruskal-Wallis秩和检验、χ²检验或Fisher确切概率法。
主要发现
- 49例HS患儿中男26例、女23例,二代测序确诊年龄3岁(28日龄,10岁),新生儿期起病31例,新生儿期后起病16例。
- 患儿起病时均有不同程度黄疸,36例存在贫血。
- 22例携带ANK1基因杂合致病变异,27例携带SPTB基因杂合致病变异,55%(27/49)为既往未见报道的新变异。
- 与新生儿期后起病组相比,新生儿期起病组男性占比、血红蛋白水平及网织红细胞比例均低[42%(13/31)比12/16、76(67,105)比108(88,114)g/L、0.06(0.04,0.10)比0.09(0.07,0.13),χ²=4.63,Z=2.27、2.08,均P<0.05]。
- 新生儿期起病组新生儿期接受光疗及输血治疗的比例均更高[100%(31/31)比1/16、58%(18/31)比2/16,χ²=42.69、8.96,均P<0.05]。
关键数值与推荐
- ANK1基因变异组和SPTB基因变异组患儿血红蛋白水平、血清总胆红素水平差异均无统计学意义(均P>0.05)。
- SPTB基因变异组中携带无义变异及移码变异患儿的血红蛋白水平低于携带剪接变异患儿(H=6.08,P=0.048)。
临床怎么用
- 对不明原因新生儿重度高胆红素血症及溶血性贫血,应考虑二代测序以明确HS等遗传性病因。
- 新生儿期起病HS贫血较重且临床诊断困难,二代测序有助于早期分子诊断。
- SPTB基因无义变异及移码变异患儿血红蛋白水平更低,需关注贫血严重程度。
局限性
- 本研究为病例系列研究,样本量有限(49例),结论需更大样本验证。
- 仅纳入经二代测序确诊的HS患儿,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To analyze the clinical and genetic characteristics of children with hereditary spherocytosis (HS) confirmed by next-generation sequencing (NGS), and to evaluate the application of NGS in diagnosing neonatal HS. Methods: A case-series study was conducted. A total of 49 HS children confirmed by NGS between June 2016 and June 2025 were enrolled from 5 centers, including the Children's Hospital of Fudan University, Guangzhou Medical University Affiliated Women and Children's Medical Center, the People's Hospital of Xinjiang Uygur Autonomous Region, Quanzhou Women's and Children's Hospital of Fujian Province, and the Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region. Clinical data were collected, including age at admission, sex, family history, age at onset, major clinical symptoms and signs, laboratory findings, and genetic test results. Children were grouped by age at onset to compare clinical characteristics, diagnostic process, and treatments. The distribution of pathogenic genes and variant types was described, and grouped according to the identified pathogenic genes and variant types, genotype-phenotype associations across genes and variant types were explored. Intergroup comparisons were performed using the Mann-Whitney U test, the Kruskal-Wallis rank-sum test, the χ² test, or Fisher's exact test. Results: Among the 49 HS children, 26 were male and 23 were female; the age when diagnosed was 3 years (28 days, 10 years). Onset occurred in the neonatal period in 31 children and after the neonatal period in 16 children. All children presented with jaundice of varying severity at onset, and 36 had anemia. Among the 31 children with neonatal-onset HS, 23 underwent NGS at onset and were diagnosed during the neonatal period; of these, 2 were clinically diagnosed with HS before the sequencing results were reported and were subsequently confirmed by sequencing, while 21 were retrospectively diagnosed based on clinical findings after the sequencing results suggested HS; 8 children were not clearly diagnosed in the neonatal period and were confirmed by NGS after the neonatal period, among which 2 were clinically diagnosed first and then confirmed by sequencing, and 6 were retrospectively diagnosed after sequencing results suggested HS. Only 4 of the 31 neonatal-onset children had received a clinical diagnosis before NGS. Twenty-two children carried heterozygous pathogenic variants in the ANK1 gene, and 27 children carried heterozygous pathogenic variants in the SPTB gene; 55% (27/49) were novel variants not previously reported. Compared with the post-neonatal-onset group, the neonatal-onset group had a lower proportion of males, lower hemoglobin levels, and a lower reticulocyte proportion (42%(13/31) vs. 12/16, 76 (67, 105) vs. 108 (88, 114) g/L, 0.06 (0.04, 0.10) vs. 0.09 (0.07, 0.13)), with statistical differences (χ²=4.63, Z=2.27 and 2.08, all P<0.05). The neonatal-onset group also had higher rates of phototherapy and transfusion during the neonatal period (100%(31/31) vs. 1/16, 58%(18/31) vs. 2/16, χ2=42.69, 8.96, both P<0.05). There were no difference in hemoglobin levels or serum total bilirubin levels between the ANK1 gene variant group and the SPTB gene variant group (both P>0.05). In the SPTB gene variant group, the hemoglobin level of children carrying nonsense variants and frameshift variants was lower than that of children carrying splice variants (H=6.08, P=0.048). Conclusions: ANK1 gene and SPTB gene are the main pathogenic genes in children with HS. Neonatal HS is characterized by more severe anemia and is difficult to diagnose clinically. NGS can effectively enable early molecular diagnosis and has important value for etiological diagnosis in neonates with unexplained severe hyperbilirubinemia and hemolytic anemia. 目的: 分析遗传性球形红细胞增多症(HS)患儿的临床与遗传学特征,评估二代测序在新生儿HS诊断中的应用情况。 方法: 病例系列研究。纳入2016年6月至2025年6月在复旦大学附属儿科医院、广州医科大学附属妇女儿童医疗中心、新疆维吾尔自治区人民医院、福建省泉州市妇幼保健院和广西壮族自治区妇幼保健院通过二代测序确诊的49例HS患儿,收集患儿入院年龄、性别、家族史、起病时间、主要临床症状及体征、实验室检查、基因检测结果等临床资料。按起病年龄分组,比较患儿的临床特征、诊断经过及治疗情况,描述致病基因及变异类型分布,并按检出的致病基因及变异类型分组,探讨不同基因及变异类型的基因型-表型关系。组间比较采用Mann-Whitney U检验、Kruskal-Wallis秩和检验、χ2检验或Fisher确切概率法。 结果: 49例HS患儿中男26例、女23例,二代测序确诊年龄3岁(28日龄,10岁),新生儿期起病31例,新生儿期后起病16例。患儿起病时均有不同程度的黄疸,36例存在贫血。新生儿期起病组的31例患儿中23例在起病时即送检二代测序,2例先临床诊断HS后由二代测序验证,21例为测序结果提示后结合临床表现回顾性确诊;8例新生儿期未明确诊断,至新生儿期后送检二代测序确诊,其中2例先临床诊断后由测序验证,6例为测序结果提示后回顾性确诊。22例携带ANK1基因杂合致病变异,27例携带SPTB基因杂合致病变异,55%(27/49)为既往未见报道的新变异。与新生儿期后起病组相比,新生儿期起病组男性占比、血红蛋白水平及网织红细胞比例均低[42%(13/31)比12/16、76(67,105)比108(88,114)g/L、0.06(0.04,0.10)比0.09(0.07,0.13),χ2=4.63,Z=2.27、2.08,均P<0.05],新生儿期接受光疗及输血治疗的比例均更高[100%(31/31)比1/16、58%(18/31)比2/16,χ2=42.69、8.96,均P<0.05]。ANK1基因变异组和SPTB基因变异组患儿血红蛋白水平、血清总胆红素水平差异均无统计学意义(均P>0.05),SPTB基因变异组中携带无义变异及移码变异患儿的血红蛋白水平低于携带剪接变异患儿(H=6.08,P=0.048)。 结论: ANK1基因和SPTB基因是HS患儿的主要致病基因。新生儿期起病HS贫血程度较重、临床诊断困难,应用二代测序可有效实现早期分子诊断,对不明原因新生儿重度高胆红素血症及溶血性贫血的病因诊断具有重要价值。.
引用
- Mo Y, Xiao FF, Wang HJ, et al. [Analysis of the clinical application of next-generation sequencing in the diagnosis of neonatal hereditary spherocytosis]. Zhonghua Er Ke Za Zhi. 2026. PMID: 41834204. doi:10.3760/cma.j.cn112140-20251031-00970
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。